Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic...

{
  "signal_id": "239febff-0047-3160-29fd-261e8e8dd37a",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-25T11:30:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/johnson--johnson-announces-tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-show-significant-improvement-in-spinal-pain-and-stiffness-in-landmark-axial-psoriatic-arthritis-psa-study-302889998.html",
    "title": "Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study",
    "excerpt": "SPRING HOUSE, Pa. , Sept. 25, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that TREMFYA ® (guselkumab) met the primary and major secondary endpoints demonstrating both improvement in axial symptoms and reduction in inflammation by MRI assessment in the Phase 4 STAR study evaluating biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA). STAR is the first and only dedicated randomized, double-blind, placebo-controlled study of its kind designed to prospectively evaluate an IL-23 inhibitor specifically in patients with axial involvement confirmed by magnetic resonance imaging (MRI). 1 These topline findings represent an important milestone in advancing disease-specific evidence for patients living with axial PsA. Detailed efficacy and safety results, including MRI findings, will be presented at an upcoming scientific congress. In the STAR study, TREMFYA met the primary endpoint evaluating improvement in a composite patient-reported disease activity score that includes spinal pain, stiffness, fatigue, joint symptoms and areas of tenderness (the Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]) a at Week 24 versus placebo. TREMFYA also met major secondary endpoints demonstrating a significant reduction in both axial symptoms, as measured by ASDAS-CRP b , and objective (MRI) inflammation of the sacroiliac joints...",
    "product": "TREMFYA",
    "summary": "Johnson & Johnson announced its drug TREMFYA® (guselkumab) met primary and major secondary endpoints in its Phase 4 STAR study for treating adults with active psoriatic arthritis and axial involvement.",
    "location": "Spring House, PA, USA",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS225644/Johnson-and-Johnson-Logo-v1.jpg?id=OA2970803&p=facebook",
    "confidence": 0.9,
    "product_data": {
      "name": "TREMFYA",
      "full_text": "TREMFYA ® (guselkumab)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-25T11:30:00Z",
    "location_data": [
      {
        "city": "Spring House",
        "state": "Pennsylvania",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-25",
    "article_sentence": "Johnson & Johnson (NYSE: JNJ ) today announced that TREMFYA ® (guselkumab) met the primary and major secondary endpoints demonstrating both improvement in axial symptoms and reduction in inflammation by MRI assessment in the Phase 4 STAR study evaluating biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA)."
  }
}

curl https://signals.autobound.ai/v1/signals/239febff-0047-3160-29fd-261e8e8dd37a \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'